News | August 23, 2024
Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Abhay Soi, who had paid an income tax of approximately Rs 400 crore in the assessment year 2023-24 has been recognised as the “Top Individual tax payers having gross tax payable > Rs 10 Lakhs"
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Subscribe To Our Newsletter & Stay Updated
